<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363178</url>
  </required_header>
  <id_info>
    <org_study_id>GC3107_P1</org_study_id>
    <nct_id>NCT03363178</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults</brief_title>
  <official_title>A Single-arm, Open-label, Single-center, Phase 1 Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) After Intradermal Administration in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin
      Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in
      48~72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>for 7 days from Day0/during study period</time_frame>
    <description>Solicited/Unsolicited Adverse Event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether the maximum Induration diameter greater than 5mm after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Induration diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether the maximum Erythema/Redness diameter greater than 5mm after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Erythema/Redness diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum diameter of Induration after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Induration diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum diameter of Erythema/Redness after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Erythema/Redness diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum diameter variation of Induration after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Induration diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum diameter variation of Erythema/Redness after TST.</measure>
    <time_frame>Day0+84days</time_frame>
    <description>Erythema/Redness diameter measured in the direction perpendicular to the arm.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>GC3107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCG Vaccine, 0.1mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3107</intervention_name>
    <description>BCG Vaccine, 0.1mL</description>
    <arm_group_label>GC3107</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 19-64 years old

          -  Informed consent form has been signed and dated

          -  Able to comply with the requirements of the study

          -  Female subjects who have negative results in Urine hCG test at screening, or
             menopausal women.

        Exclusion Criteria:

          -  Subjects who have positive results(;induration diameter over 5mm) in Tuberculin Skin
             Test(TST) at screening

          -  Subjects who shown abnormal results(including inactive tuberculosis) on Chest X-ray at
             screening

          -  Subjects who received a vaccination(including live vaccine) within 28 days before
             enrollment

          -  Subjects who are on antituberculosis drugs

          -  Immunocompromised subjects with immunodeficiency disease or subjects receiving
             immunosuppressive or immunomodulating therapy

          -  Subjects with severe chronic disease who are considered by investigator to be
             ineligible for the study

          -  Pregant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo Kim, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoonjung Nam, Pharm.D</last_name>
    <phone>+81-260-9143</phone>
    <email>clairenam@greencross.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Joo Kim, M.D. Ph.D.</last_name>
      <email>wjkim@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Woo Joo Kim, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

